Join on WhatsApp
Join on Telegram
Rabat – T2S Group Holding, one of Morocco’s leading MedTech companies, received the green light from the Moroccan Capital Market Authority (AMMC) on Monday, clearing a key step for its initial public offering. The operation, valued at nearly MAD 1.1 billion ($117 million), combines new capital with the sale of existing shares.
The structure of the deal points to a dual objective. Part of the funds, close to MAD 350 million ($37 million), will come from a capital increase open to the public. The rest, around MAD 750 million ($80 million), will result from the sale of shares already held by current stakeholders. Together, the transaction aims to give the group both financial flexibility and broader market visibility.
Behind the figures stands a company that has quietly built a strong position in Morocco’s healthcare ecosystem. Founded in 1992, T2S Group has grown from a local initiative into a well-established MedTech operator, with activities that span equipment supply, technical services, and industrial capabilities.
Its approach rests on a simple but demanding idea: provide hospitals and clinics with advanced tools that meet international standards, while ensuring that these technologies remain usable, reliable, and adapted to local realities. This includes the delivery of equipment, as well as installation, maintenance, and long-term technical support.
Over time, the group has expanded into several specialized segments. Its portfolio covers imaging and oncology equipment, operating room technologies, and a wide range of medical devices, including tools used in minimally invasive procedures. It also operates in laboratory diagnostics, nuclear medicine products, and hospital digital systems.
This diversification reflects the evolution of healthcare needs, where technology plays a central role across the entire patient pathway, from diagnosis to treatment and follow-up.
To sustain this model, T2S Group relies on partnerships with more than 40 international manufacturers, among them major names in the global MedTech industry. These collaborations allow the company to offer a broad catalog that now exceeds 8,000 product references.
The group’s footprint extends beyond Morocco. It has built a presence in more than 20 African countries, supported by a centralized logistics platform and a workforce of over 400 employees. This regional reach forms a key part of its next phase.
In the coming years, T2S Group plans to strengthen its core activities while introducing new technologies, particularly in high-value medical segments. The group also intends to expand further across African markets and pursue targeted acquisitions when opportunities arise.
The stock market listing appears as a tool to support these ambitions. By opening its capital to a wider base of investors, the company seeks a new stage of institutional development as it positions itself in a sector where demand continues to grow alongside demographic and healthcare transitions.
